CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
暂无分享,去创建一个
Matthias Cavassini | Urs Karrer | Hansjakob Furrer | Bernard Hirschel | Pietro Vernazza | Enos Bernasconi | Sabine Yerly | Praphan Phanuphak | Jintanat Ananworanich | Thomas Perneger | Luc Perrin | Andrew Hill | David Cooper | T. Perneger | H. Furrer | P. Vernazza | E. Bernasconi | S. Yerly | L. Perrin | B. Hirschel | J. Ananworanich | K. Ruxrungtham | A. Gayet-Ageron | M. Cavassini | S. Sirivichayakul | P. Phanuphak | W. Prasithsirikul | A. Hill | Angèle Gayet-Ageron | Michelle Le Braz | Wisit Prasithsirikul | Ploenchan Chetchotisakd | Sasisopin Kiertiburanakul | Warangkana Munsakul | Phitsanu Raksakulkarn | Somboon Tansuphasawasdikul | Sunee Sirivichayakul | Daniel Genné | Reto Nüesch | Dominic Leduc | Claudette Satchell | Kiat Ruxrungtham | D. Cooper | P. Chetchotisakd | S. Kiertiburanakul | D. Genné | C. Satchell | R. Nüesch | Warangkana Munsakul | P. Raksakulkarn | Somboon Tansuphasawasdikul | Urs Karrer | Dominic Leduc | David Cooper
[1] M. Loutfy,et al. Can Structured Treatment Interruptions (STIs) Be Used as a Strategy to Decrease Total Drug Requirements and Toxicity in HIV Infection? , 2002, Journal of the International Association of Physicians in AIDS Care.
[2] J. Fellay,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[3] N. Breslow,et al. Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.
[4] John W. Ward,et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[5] J. Fleishman,et al. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. , 2000 .
[6] M Egger,et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. , 1999, JAMA.
[7] B. Yip,et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up , 2002, AIDS.
[8] K. Floyd,et al. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence , 2002, The Lancet.
[9] N. E. Breslow. Statistical Methods in Cancer Research , 1986 .
[10] B. Clotet,et al. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. , 2004, AIDS research and human retroviruses.
[11] J. Ananworanich,et al. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] T. Perneger,et al. Biphasic decline of CD4 cell count during scheduled treatment interruptions , 2005, AIDS.
[13] A. Telenti,et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. , 2003, Archives of internal medicine.
[14] Michelle Le Braz,et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial , 2003, AIDS.
[15] C. Cohen,et al. Retroviral Rebound Syndrome after Cessation of Suppressive Antiretroviral Therapy in Three Patients with Chronic HIV Infection , 2000, Annals of Internal Medicine.
[16] B. Autran,et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. , 2005, Journal of Infectious Diseases.